Low-grade fibromyxoid sarcoma (LGFMS) is very uncommon in the pediatric population with only 20% of reported cases under the age of 18. The youngest reported case to date has been in a 4-year-old child. Lesions are usually slow growing and asymptomatic, and locations described in children have included paravertebral, thigh and intrathoracic. Although benign in appearance, these lesions can behave aggressively, with local recurrence and distant metastases primarily to lungs. These lesions can be resistant to the usual chemotherapy and radiotherapy with surgical resection being the treatment of choice. We report a case of a 5-year-old boy who presented with a mass in the left buttock.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00383-011-3024-zDOI Listing

Publication Analysis

Top Keywords

low-grade fibromyxoid
8
fibromyxoid sarcoma
8
sarcoma deceptively
4
deceptively benign
4
benign tumor
4
tumor 5-year-old
4
5-year-old child
4
child low-grade
4
sarcoma lgfms
4
lgfms uncommon
4

Similar Publications

Sclerosing epithelioid fibrosarcoma (SEF) was originally described as a peculiar variant of fibrosarcoma in 1995. Subsequent studies showed that conventional SEF was associated with both immunohistochemical expression of MUC4 and EWSR1/FUS gene rearrangements with CREB3L1 as the predominant fusion partner. Since then, a distinct group of fibrous tumors characterized by YAP1::KMT2A and KMT2A::YAP1 gene rearrangements and SEF-like morphology has been described.

View Article and Find Full Text PDF

The aim of the study was to report the outcome of primary localized low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid LGFMS/SEF (H-LGFMS/SEF). Patients with primary localized LGFMS, SEF, or H-LGFMS/SEF, surgically treated with curative intent from January 2000 to September 2022, were enrolled from 14 countries and 27 institutions. Pathologic inclusion criteria were predefined by expert pathologists.

View Article and Find Full Text PDF

High-Throughput Hybridization Assay as First-Line Diagnostic Test for Sarcomas: Clinical Assessment in a Tertiary Referral Center.

Arch Pathol Lab Med

October 2024

From the Department of Pathology, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC-Universidad de Sevilla, Seville, Spain (Salguero-Aranda, Perez, Vargas-Padilla, Beltrán-Povea, Delgado-Bellido, Marcilla, Civantos, de Álava, Díaz-Martín).

Article Synopsis
  • Sarcomas are rare tumors that are hard to diagnose due to their varied appearances; traditional diagnostic methods have limitations in accurately identifying them.
  • The study aimed to enhance the diagnostic capabilities of the NanoString nCounter technology by incorporating 188 probes to detect specific gene fusions associated with various types of sarcomas, which were validated through retrospective and prospective sample testing.
  • The results showed that this optimized NanoString approach achieved over 88% sensitivity and 100% specificity, proving to be more effective than standard methods, especially for identifying crucial gene fusions in solitary fibrous tumors and low-grade fibromyxoid sarcomas.
View Article and Find Full Text PDF

Low-grade fibromyxoid sarcoma (LGFMS) represents an exceptionally rare soft-tissue tumor, challenging to diagnose, and notorious for relentless recurrence and proliferation postsurgical resection. Primary symptoms of LGFMS include nasal congestion and rhinorrhea, accompanied by cheek numbness and distension. In this article, we report the diagnosis and treatment of a case of low-grade LGFMS originating in the maxillary sinus (MS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!